Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.

Anticancer research - 1 Dec 2017

Ponti Giovanni, Manfredini Marco, Greco Stefano, Pellacani Giovanni, Depenni Roberta, Tomasi Aldo, Maccaferri Monia, Cascinu Stefano

Abstract excerpt

BACKGROUND/AIM: The mutational status of stage III and IV melanomas should be recognized in order to allow for targeted therapies. The aim of our study was the characterization of BRAF, NRAS and C-KIT melanoma patients, in order to define their optimal management. PATIENTS AND METHODS: Between 1991 and 2015, 63 mutated melanoma patients were treated and monitored during their diagnostic and therapeutic management...

Topics

Aged
Antineoplastic Agents
Female
GTP Phosphohydrolases
Humans
Kaplan-Meier Estimate
Male
Melanoma
Membrane Proteins
Middle Aged
Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Mutation

Prognosis

Proto-Oncogene Proteins B-raf

Proto-Oncogene Proteins c-kit

Skin Neoplasms

Source

Identifiers

PMID: 29187493
DOI: 10.21873/anticanres.12175

Genes

BRAF
KIT
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival.PMID 29187493Read ↗

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Semantic proximity Read ↗

Melanoma.Semantic proximity Read ↗

<em>NRAS</em>-mutant melanoma: current challenges and future prospectSemantic proximity Read ↗

Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.Semantic proximity Read ↗

Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.Semantic proximity Read ↗

Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.Semantic proximity Read ↗

Effects of BRAF V600E and NRAS mutational status on the progression‑free survival and clinicopathological characteristics of patients with melanomaSemantic proximity Read ↗

Advances in targeted therapy for melanoma.Semantic proximity Read ↗

Current Perspectives and Novel Strategies of NRAS-Mutant MelanomaSemantic proximity Read ↗

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.Semantic proximity Read ↗

Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular featuresSemantic proximity Read ↗

KIT and Melanoma: Biological Insights and Clinical Implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.